CHAPEL HILL, N.C., Jan. 12, 2018 /PRNewswire/ — Biopharmaceutical organizations rely on scientific publications to inform the medical community about critical clinical trial data. It is the data from early phases of drug development that critical stakeholders such as physicians and payers learn about new products. and the information serves as the building blocks for how a new product will be positioned in the marketplace.
But with growing calls for transparency and data disclosure, global publications leaders find themselves in a balancing act— how to ensure their publications demonstrate both scientific credibility and commercial viability. To help publications leaders navigate this landscape, Best Practices, LLC conducted a primary research project to investigate how top biopharmaceutical companies shape their global scientific publication strategies to maintain credibility in the scientific community and, at the same time, deliver publications that drive brand success.
The study found that open access platforms are gaining popularity for publication processes; 44% of companies in the study believe such platforms will impact publication strategy going forward. Part of the allure for open access platforms is they make information readily available to physicians and patients alike. In the wake of open access platforms, companies foresee an impact on areas such as journal selection, publication approval and delivery, and speed of data disclosure.
In particular, this 85-page study provides benchmarks around publications structure and leadership; staffing and budget levels; publication strategy creation and data delivery; publication channel utilization across product lifecycle; and measuring publication effectiveness.
“Best Practices in Scientific Publications Strategy: Managing Reputation, Clinical Trial Results and Commercial Relevance” will help publication leaders better understand how an effective publications strategy can boost an organization’s scientific credibility and a new product’s commercial viability.
Key topics in the study include:
- Optimal structure for the global publications function
- Transition of global publications from commercial to clinical
- Key internal stakeholders who contribute to publications strategy
- Tactics for handling publication of neutral or negative clinical trial results
- Impact of transparency guidelines on publications, planning and delivery
- Strategy changes for the new marketplace
For this study, Best Practices, LLC engaged 20 leaders from 19 biopharmaceutical companies through a benchmarking survey and executive interviews.
To access the full report or to download a complimentary summary containing insights found in this report, click on the following link: http://www.best-in-class.com/rr1480.htm.
For related research, visit the Best Practices, LLC Web site at www.best-in-class.com/.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC’s clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.
SOURCE Best Practices, LLC